MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.

MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.

MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.

MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.

GNE-495 is a potent and selective inhibitor of MAP4K4 with an IC50 value of 3.7 nM. It demonstrates excellent potency and good Pharmacokinetics in in vivo efficacy in a retinal angiogenesis model.

GNE-495 is a potent and selective inhibitor of MAP4K4 with an IC50 value of 3.7 nM. It demonstrates excellent potency and good Pharmacokinetics in in vivo efficacy in a retinal angiogenesis model.

GNE-495 is a potent and selective inhibitor of MAP4K4 with an IC50 value of 3.7 nM. It demonstrates excellent potency and good Pharmacokinetics in in vivo efficacy in a retinal angiogenesis model.

GNE-495 is a potent and selective inhibitor of MAP4K4 with an IC50 value of 3.7 nM. It demonstrates excellent potency and good Pharmacokinetics in in vivo efficacy in a retinal angiogenesis model.

Flonoltinib (JAK2/FLT3-IN-1) is a potent and selective dual inhibitor of JAK2 and FLT3, with IC50 of of 0.8, 1.4, and 15 nM against JAK2, JAK2V617F, and FLT3, respectively, in in vitro kinase assays. It also inhibits cell proliferation and induces G2/M cell cycle arrest and apoptosis in Hemophagocytic Lymphohistiocytosis (HLH) patients’ CD8+T cells, CTLL2 cells, […]

Flonoltinib (JAK2/FLT3-IN-1) is a potent and selective dual inhibitor of JAK2 and FLT3, with IC50 of of 0.8, 1.4, and 15 nM against JAK2, JAK2V617F, and FLT3, respectively, in in vitro kinase assays. It also inhibits cell proliferation and induces G2/M cell cycle arrest and apoptosis in Hemophagocytic Lymphohistiocytosis (HLH) patients’ CD8+T cells, CTLL2 cells, […]